Background: Menière's disease (MD) is clinically characterized by the triad sensorineural hearing loss, tinnitus and/or aural fullness, and vertigo. Endolymphatic hydrops (EH) is the histopathological basis associated with MD, which can be demonstrated on magnetic resonance imaging (MRI). Currently, most studies are done on a 3-T MRI scanner and to date it is believed that EH can only be demonstrated on a 3-T magnet. We report the feasibility of demonstrating EH on a 1.5-T scanner using the standard 20-channel head and neck coil and the current standard 4-h delayed intravenous gadolinium-enhanced three-dimensional fluid-attenuated inversion recovery (3D-FLAIR) sequence.

Purpose: To investigate whether current standard 4-h delayed intravenous gadolinium-enhanced 3D-FLAIR imaging can demonstrate endolymphatic hydrops on a 1.5-T MRI scanner.

Material And Methods: The 3D-FLAIR sequence was taken from a 3-T MRI protocol and tested on a volunteer patient with clinically "definite" MD, after 4-h delayed intravenous contrast injection. Good image quality was obtained after reducing both the matrix and the bandwidth, with clear demonstration of EH. Subsequently, eight more patients with unilateral disease were imaged. Five patients had "definite" MD and four had "probable" MD.

Results: We imaged nine patients with unilateral disease and detected EH in eight of nine ears. One patient with "probable" MD did not show any abnormality, but the images were degraded by motion artifacts.

Conclusion: At a cost of 2 min extra scanning time compared to a 3-T scanner, EH can be confidently demonstrated with the current standard 3D-FLAIR sequence on a 1.5-T magnet.

Download full-text PDF

Source
http://dx.doi.org/10.1177/02841851211016478DOI Listing

Publication Analysis

Top Keywords

current standard
12
4-h delayed
12
delayed intravenous
12
menière's disease
8
endolymphatic hydrops
8
3-t mri
8
standard 4-h
8
intravenous gadolinium-enhanced
8
3d-flair sequence
8
patients unilateral
8

Similar Publications

Development of a Synthetic VP1 Protein Peptide-Based ELISA to Detect Antibodies Against Porcine Bocavirus Group 3.

Viruses

December 2024

Xinjiang Key Laboratory of New Drug Study and Creation for Herbivorous Animals (XJ-KLNDSCHA), College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi 830052, China.

Porcine bocavirus (PBoV), classified within the genus Bocaparvovirus, has been reported worldwide. PBoV has been divided into group 1, group 2, and group 3. PBoV group 3 (G3) viruses are the most prevalent in China.

View Article and Find Full Text PDF

A limited number of studies focus on estimating the costs of interventions to increase childhood immunization coverage in low- and middle-income countries (LMICs). Existing reviews often compare estimated costs but lack information on the methods used. The objective of this review is to summarize the methods used in costing studies that assessed interventions to reach zero-dose (ZD) children.

View Article and Find Full Text PDF

The Strategic Advisory Group of Experts (SAGE) on Immunization-Past, Present and Future.

Vaccines (Basel)

December 2024

Department of Immunization, Vaccines and Biologicals, World Health Organization, CH-1211 Geneva, Switzerland.

Background/objectives: In November 1999, WHO established the Strategic Advisory Group of Experts (SAGE) on Immunization as a multidisciplinary group of experts to provide high-level recommendations on vaccines and immunization.

Methods: This review provides an overview of SAGE's work in the past 25 years. It further outlines the processes and methods currently used by SAGE and highlights some of its major achievements.

View Article and Find Full Text PDF

Background: The Vero cell rabies vaccine is currently the most widely used human rabies vaccine. However, owing to the presence of residual host cell DNA (HCD) in the final product and the potential tumorigenicity of the DNA of high-passage Vero cells, the WHO not only sets a limit on the number of times cells used in production can be passaged, but also imposes strict requirements on the amount of residual HCD in the final vaccine product.

Objectives: To systematically reduce the HCD level in the final vaccine product, multiple purification steps are included in the vaccine production process.

View Article and Find Full Text PDF

Background/objectives: Host cell protein (HCP) content is a major attribute for biological and vaccine products that must be extensively characterized prior to product licensure. Enzyme Linked Immunosorbent Assay (ELISA) and Mass Spectrometry (MS) are conventional methods for quantitative host cell protein analysis in biologic and vaccine products. Both techniques are usually very tedious, labor-intensive, and challenging to transfer to other laboratories.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!